Skip to main content
Frontiers in Immunology logoLink to Frontiers in Immunology
. 2024 Apr 17;15:1403324. doi: 10.3389/fimmu.2024.1403324

Corrigendum: Therapeutic strategies targeting folate receptor α for ovarian cancer

Jia Mai 1, Limei Wu 1,2, Ling Yang 1, Ting Sun 3, Xiaojuan Liu 1, Rutie Yin 1, Yongmei Jiang 1,*, Jinke Li 1,*, Qintong Li 1,*
PMCID: PMC11061861  PMID: 38694498

In the published article, there was an error in Figure 1 as published. PCTF is a symporter that transport H+ ion together with the folate transporter, we made a mistake with the direction of one arrow, by making it like PCFT is portrayed as an antiporter. The corrected Figure 1 and its caption appear below.

Figure 1.

Figure 1

The three types of folate transporters. The uptake of extracellular folate is achieved mainly through three types of folate transporters. (1) RFC, an anion antiporter that uses a gradient of higher organic phosphate in the cell to transport folate into the cell while transporting organic phosphate out of the cell, (2) PCFT, a proton-coupled transporter, (3) folate receptor family (only FRα is shown). They transfer folate through endocytosis in selected tissues.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA

RESOURCES